Skip to content

Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy

A Randomized Controlled Double-blinded Trial Comparing the Effect of on Demand vs Deep Neuromuscular Relaxation on Rating of Surgical and Anesthesia Conditions in Patients Undergoing Thoraco-laparoscopic Esophagectomy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02320734
Acronym
DEPTH
Enrollment
66
Registered
2014-12-19
Start date
2015-02-28
Completion date
2016-09-30
Last updated
2016-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer, Neuromuscular Block, Surgery

Keywords

surgical rating scale, neuromuscular relaxation, Anaesthesia, minimally invasive esophagectomy

Brief summary

Rationale: Endoscopic (thoraco-laparoscopic) esophageal surgery is a high risk procedure where the use of deep neuromuscular block (NMB) may increase field visibility and anaesthesia conditions. Under these conditions, boluses of muscle relaxants can be given on indication only OR by continuous infusion. We hypothesize that deep NMB by continuous infusion of rocuronium as compared to on demand bolus administration facilitates surgical and anesthesia conditions during thoraco-laparoscopic esophageal resection but higher doses of sugammadex are needed to reverse NMB at the end of surgery. Objective: Primary objective is to evaluate the use of deep muscle relaxation versus on indication only on surgical and anesthesia conditions in patients for endoscopic esophageal resection. Secondary objectives are to evaluate the (hypothetical) dose of sugammadex needed in both groups in an economical perspective and to compare the intra-operative cardiac and respiratory incidents and post-operative complication rate of both groups. Study design: a single-center randomized controlled double-blinded intervention study. Study population: All patients \> 18 years to undergo a thoracolaparoscopic esophageal resection.I Intervention: Patients are randomized to receive either continuous infusion of rocuronium 0.6 mg/kg/hr (group 1) or continuous infusion of NaCl 0.9% 0.06 ml/kg/hr (group 2). On demand boluses of Rocuronium 0.3 mg/kg can be given in both groups. Main study parameters/endpoints: The primary outcome parameter of this study is the SRS during the abdominal phase of thoracolaparoscopic esophageal surgery. Secondary outcomes measured are SRS during the thoracic phase, the number of on demand boluses infused, the dose of Sugammadex needed in both groups to reach a TOF of \> 90%, duration of surgery, a cost-analysis, the incidence of intra-operative cardiac and respiratory incidents and the ability of surgeons to estimate which neuromuscular blocking regime was given to the patient.

Interventions

DRUGRocuronium

Rocuronium given continuously to reach deep neuromuscular block

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients, undergoing elective thoraco-laparoscopic esophageal resection (either Ivor Lewis or McKeown variant) * Written informed consent

Exclusion criteria

* pregnancy * Known allergies for aminosteroid-type muscle relaxants or sugammadex. * Severe kidney dysfunction (GFR \< 30), patients on dialysis * Liver function disorders * Myasthenia Gravis or other (neuro)muscular diseases * Patients with carcinomatosis * Use of anti-epileptics and lithium or drugs containing Kinin

Design outcomes

Primary

MeasureTime frame
Rating of surgical conditions (SRS) during the abdominal phase of the operation.during operation

Secondary

MeasureTime frameDescription
Rating of SRS during thoracic phase of the operation.during operation
Number of on demand boluses infused, indication of on demand bolus administrationduring operation
Rating of anesthesia conditionsduring operationpeak and mean respiratory pressure, incidence peak insufflation pressure \>35 mmHg. Depth of NBM at the end of surgery. Time until spontaneous breathing, time until extubation. Peroperative cardiac and respiratory incidents, peroperative surgical complications.Tiem to reversal of NMB, % of recurarisation
Costs (euro's) associated with use of Rocuronium, Sugammadex, operation time and length of stay ICU.during operation and an average of 4 weeks thereafteramount of rocuronium used (mg); Dose of sugammadex needed (mg), duration of surgery, hypothetical need for post-operative ventilation if sugammadex would not be available(%).
Number of correct estimates of group randomization by surgeonsdirectly after operationSurgeons will guess in which group the patient was randomized (%) and the reason for this choice will be registrated. Accordingly we can estimate whether the surgeons complaints of inadequate NMB are justified and additionally, the chance of bias affecting main outcome parameter.

Other

MeasureTime frame
need for re-intubationparticipants will be followed for the duration of hospital stay, an expected average of 4 weeks
post-operative surgical complicationsparticipants will be followed for the duration of hospital stay, an expected average of 4 weeks
VAS-scores24-hours post operation
Abdominal and thoracic insufflation pressuresDuring operation
length of stay ICU/PACUparticipants will be followed for the duration of hospital stay, an expected average of 4 weeks

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026